Operating Income: The income after operating expenses.
C4 Therapeutics, Inc. (CCCC) had Operating Income of $-37.71M for the most recently reported fiscal quarter, ending 2024-12-31.
| Income Statement Financials | |
$5.18M |
|
$-34.57M |
|
-- |
|
$5.18M |
|
$42.89M |
|
|
Operating Income |
$-37.71M |
$3.27M |
|
$-34.44M |
|
$-34.44M |
|
$-34.57M |
|
$-34.57M |
|
$-34.57M |
|
$-34.57M |
|
$-37.71M |
|
$-38.31M |
|
69.37M |
|
69.37M |
|
$-0.50 |
|
$-0.50 |
|
| Balance Sheet Financials | |
$257.77M |
|
$5.84M |
|
$91.83M |
|
$349.60M |
|
$45.18M |
|
-- |
|
$88.44M |
|
$133.62M |
|
$215.99M |
|
$215.99M |
|
$215.99M |
|
70.63M |
|
| Cash Flow Statement Financials | |
$-65.16M |
|
$-51.27M |
|
$45.34M |
|
$130.03M |
|
$58.94M |
|
$-71.09M |
|
$29.66M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.71 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-728.39% |
|
-728.39% |
|
-- |
|
-665.29% |
|
-667.82% |
|
$-65.34M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
1.67 |
|
53.93 |
|
-16.01% |
|
-16.01% |
|
-9.89% |
|
-16.01% |
|
$3.06 |
|
$-0.94 |
|
$-0.94 |
|